^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Lymphoma |
| Drug: | IPH6501 (CD20 inhibitor, NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies
Published date:
11/03/2022
Excerpt:
In vivo treatment with a mouse surrogate of IPH6501 induced peripheral NK cell proliferation and activation, and demonstrated potent antitumor efficacy in a xenograft mouse model using the aggressive human B-lymphoma CD20+ RAJI cell line engrafted subcutaneously....IPH6501 is thus a promising biologic designed to harness the anti-tumor functions of NK cells in CD20+ B cell malignancies.
